AU2012296804B2 - Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease - Google Patents
Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease Download PDFInfo
- Publication number
- AU2012296804B2 AU2012296804B2 AU2012296804A AU2012296804A AU2012296804B2 AU 2012296804 B2 AU2012296804 B2 AU 2012296804B2 AU 2012296804 A AU2012296804 A AU 2012296804A AU 2012296804 A AU2012296804 A AU 2012296804A AU 2012296804 B2 AU2012296804 B2 AU 2012296804B2
- Authority
- AU
- Australia
- Prior art keywords
- ethyl
- thiadiazol
- phenyl
- piperazine
- difluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 25
- 238000011282 treatment Methods 0.000 title claims description 16
- 208000034799 Tauopathies Diseases 0.000 title description 14
- SQCOTEVTVMIEIC-UHFFFAOYSA-N piperazine;1,3-thiazole Chemical class C1=CSC=N1.C1CNCCN1 SQCOTEVTVMIEIC-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 203
- 229910052736 halogen Inorganic materials 0.000 claims description 171
- 150000002367 halogens Chemical group 0.000 claims description 170
- 125000000217 alkyl group Chemical group 0.000 claims description 114
- -1 tetrahydropyran-4-yl Chemical group 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 60
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 41
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 41
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 35
- 125000004432 carbon atom Chemical group C* 0.000 claims description 33
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 32
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 31
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 14
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 14
- 206010034010 Parkinsonism Diseases 0.000 claims description 14
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 14
- 210000000349 chromosome Anatomy 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 14
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 14
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- YEFCKUSLRGHUOF-UHFFFAOYSA-N 5-[4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl]-n-[4-(trifluoromethyl)cyclohexyl]-1,2,4-thiadiazol-3-amine Chemical compound C1=C(F)C(F)=CC=C1CCN1CCN(C=2SN=C(NC3CCC(CC3)C(F)(F)F)N=2)CC1 YEFCKUSLRGHUOF-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- QJEWVIQTNFMEPI-UHFFFAOYSA-N 5-[4-[2-(4-chlorophenyl)ethyl]piperazin-1-yl]-n-(cyclopropylmethyl)-1,2,4-thiadiazol-3-amine Chemical compound C1=CC(Cl)=CC=C1CCN1CCN(C=2SN=C(NCC3CC3)N=2)CC1 QJEWVIQTNFMEPI-UHFFFAOYSA-N 0.000 claims description 6
- LBWMYJRACYNNGO-UHFFFAOYSA-N 5-[4-[2-(4-chlorophenyl)ethyl]piperazin-1-yl]-n-cyclohexyl-1,2,4-thiadiazol-3-amine Chemical compound C1=CC(Cl)=CC=C1CCN1CCN(C=2SN=C(NC3CCCCC3)N=2)CC1 LBWMYJRACYNNGO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- JJYWVNXDPDHROP-UHFFFAOYSA-N 5-[4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl]-3-[4-(trifluoromethyl)piperidin-1-yl]-1,2,4-thiadiazole Chemical compound C1=C(F)C(F)=CC=C1CCN1CCN(C=2SN=C(N=2)N2CCC(CC2)C(F)(F)F)CC1 JJYWVNXDPDHROP-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 50
- 230000015572 biosynthetic process Effects 0.000 description 32
- 238000003786 synthesis reaction Methods 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 230000002776 aggregation Effects 0.000 description 14
- 238000004220 aggregation Methods 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 8
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 8
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 8
- 239000000969 carrier Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 102000013498 tau Proteins Human genes 0.000 description 7
- 108010026424 tau Proteins Proteins 0.000 description 7
- 150000004867 thiadiazoles Chemical class 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- FOVOGDCYFOXEKN-UHFFFAOYSA-N 1-[2-(4-methoxyphenyl)ethyl]piperazine;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1CCN1CCNCC1 FOVOGDCYFOXEKN-UHFFFAOYSA-N 0.000 description 5
- JNMBEQVBTVHKSO-UHFFFAOYSA-N 3-(4,4-difluoropiperidin-1-yl)-5-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(OC)=CC=C1CCN1CCN(C=2SN=C(N=2)N2CCC(F)(F)CC2)CC1 JNMBEQVBTVHKSO-UHFFFAOYSA-N 0.000 description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 229930002330 retinoic acid Natural products 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229960001727 tretinoin Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MIHBBNWDWBWWDR-UHFFFAOYSA-N 3-butyl-5-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]-1,2,4-thiadiazole Chemical compound CCCCC1=NSC(N2CCN(CCC=3C=C(OC)C=CC=3)CC2)=N1 MIHBBNWDWBWWDR-UHFFFAOYSA-N 0.000 description 4
- WXJQONRWNBRYGG-UHFFFAOYSA-N 3-butyl-5-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]-1,2,4-thiadiazole Chemical compound CCCCC1=NSC(N2CCN(CCC=3C=CC(OC)=CC=3)CC2)=N1 WXJQONRWNBRYGG-UHFFFAOYSA-N 0.000 description 4
- IKRRSWSXAOBWAT-UHFFFAOYSA-N 5-[4-[2-(4-chlorophenyl)ethyl]piperazin-1-yl]-n-(oxan-4-yl)-1,2,4-thiadiazol-3-amine Chemical compound C1=CC(Cl)=CC=C1CCN1CCN(C=2SN=C(NC3CCOCC3)N=2)CC1 IKRRSWSXAOBWAT-UHFFFAOYSA-N 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 150000004885 piperazines Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- OABUKBBBSMNNPM-UHFFFAOYSA-N 4,4-difluoropiperidin-1-ium;chloride Chemical compound Cl.FC1(F)CCNCC1 OABUKBBBSMNNPM-UHFFFAOYSA-N 0.000 description 3
- GCYFIEPZDGNZSR-UHFFFAOYSA-N 5-[4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl]-3-piperidin-1-yl-1,2,4-thiadiazole Chemical compound C1=C(F)C(F)=CC=C1CCN1CCN(C=2SN=C(N=2)N2CCCCC2)CC1 GCYFIEPZDGNZSR-UHFFFAOYSA-N 0.000 description 3
- BHLWOWBLXHQESX-UHFFFAOYSA-N 5-[4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl]-3-pyrrolidin-1-yl-1,2,4-thiadiazole Chemical compound C1=C(F)C(F)=CC=C1CCN1CCN(C=2SN=C(N=2)N2CCCC2)CC1 BHLWOWBLXHQESX-UHFFFAOYSA-N 0.000 description 3
- GRNYUELUPSPSIB-UHFFFAOYSA-N 5-[4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl]-n-(oxan-4-yl)-1,2,4-thiadiazol-3-amine Chemical compound C1=C(F)C(F)=CC=C1CCN1CCN(C=2SN=C(NC3CCOCC3)N=2)CC1 GRNYUELUPSPSIB-UHFFFAOYSA-N 0.000 description 3
- ATXUJYJENOYPCF-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]-3-(oxan-4-yl)-1,2,4-thiadiazole Chemical compound C1=CC(F)=CC=C1CCN1CCN(C=2SN=C(N=2)C2CCOCC2)CC1 ATXUJYJENOYPCF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006951 hyperphosphorylation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZXYICRUHFGEWJE-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)ethyl]piperazine;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC(CCN2CCNCC2)=C1 ZXYICRUHFGEWJE-UHFFFAOYSA-N 0.000 description 2
- WAVNYVVEHJJGGJ-UHFFFAOYSA-N 3-cyclohexyl-5-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(OC)=CC=C1CCN1CCN(C=2SN=C(N=2)C2CCCCC2)CC1 WAVNYVVEHJJGGJ-UHFFFAOYSA-N 0.000 description 2
- OLGUNEMEKPJVTK-UHFFFAOYSA-N 3-cyclopropyl-5-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]-1,2,4-thiadiazole Chemical compound COC1=CC=CC(CCN2CCN(CC2)C=2SN=C(N=2)C2CC2)=C1 OLGUNEMEKPJVTK-UHFFFAOYSA-N 0.000 description 2
- QHXMCLLYQYHOPB-UHFFFAOYSA-N 3-cyclopropyl-5-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(OC)=CC=C1CCN1CCN(C=2SN=C(N=2)C2CC2)CC1 QHXMCLLYQYHOPB-UHFFFAOYSA-N 0.000 description 2
- KMUKXPQVPQUCDB-UHFFFAOYSA-N 4-(trifluoromethyl)piperidine;hydrochloride Chemical compound Cl.FC(F)(F)C1CCNCC1 KMUKXPQVPQUCDB-UHFFFAOYSA-N 0.000 description 2
- HDJRNMVQLGESEX-UHFFFAOYSA-N 4-chlorothiadiazole Chemical class ClC1=CSN=N1 HDJRNMVQLGESEX-UHFFFAOYSA-N 0.000 description 2
- IXENWFQXVCOHAZ-UHFFFAOYSA-N 4-fluoropiperidine;hydrochloride Chemical compound Cl.FC1CCNCC1 IXENWFQXVCOHAZ-UHFFFAOYSA-N 0.000 description 2
- LAAWMDOIRCTKSB-UHFFFAOYSA-N 5-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]-3-(oxan-4-yl)-1,2,4-thiadiazole 5-[4-[2-(2-methoxypyridin-4-yl)ethyl]piperazin-1-yl]-3-(oxan-4-yl)-1,2,4-thiadiazole Chemical compound COC1=NC=CC(=C1)CCN1CCN(CC1)C1=NC(=NS1)C1CCOCC1.COC1=CC=C(C=C1)CCN1CCN(CC1)C1=NC(=NS1)C1CCOCC1 LAAWMDOIRCTKSB-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 101150051438 CYP gene Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000017004 dementia pugilistica Diseases 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- JCLIIXKOVPCLDA-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-[4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl]-1,2,4-thiadiazol-3-amine Chemical compound C1=C(F)C(F)=CC=C1CCN1CCN(C=2SN=C(NCC3CC3)N=2)CC1 JCLIIXKOVPCLDA-UHFFFAOYSA-N 0.000 description 2
- VMQMYHZYUYKLLC-UHFFFAOYSA-N n-butyl-5-[4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl]-n-ethyl-1,2,4-thiadiazol-3-amine Chemical compound CCCCN(CC)C1=NSC(N2CCN(CCC=3C=C(F)C(F)=CC=3)CC2)=N1 VMQMYHZYUYKLLC-UHFFFAOYSA-N 0.000 description 2
- XYQJZUINFWBTFN-UHFFFAOYSA-N n-cyclohexyl-5-[4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl]-1,2,4-thiadiazol-3-amine Chemical compound C1=C(F)C(F)=CC=C1CCN1CCN(C=2SN=C(NC3CCCCC3)N=2)CC1 XYQJZUINFWBTFN-UHFFFAOYSA-N 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000007991 neuronal integrity Effects 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 2
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 2
- RYFZYYUIAZYQLC-UHFFFAOYSA-N perchloromethyl mercaptan Chemical compound ClSC(Cl)(Cl)Cl RYFZYYUIAZYQLC-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical class C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- OXHPTABOQVHKLN-UHFFFAOYSA-N 1-(2-bromoethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCBr)C=C1 OXHPTABOQVHKLN-UHFFFAOYSA-N 0.000 description 1
- MACVYUROJLHHKH-UHFFFAOYSA-N 1-[2-(2-methoxypyridin-4-yl)ethyl]piperazine;trihydrochloride Chemical compound Cl.Cl.Cl.C1=NC(OC)=CC(CCN2CCNCC2)=C1 MACVYUROJLHHKH-UHFFFAOYSA-N 0.000 description 1
- BJMPGMOWXAYATG-UHFFFAOYSA-N 1-[2-(4-fluorophenyl)ethyl]piperazine;dihydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1CCN1CCNCC1 BJMPGMOWXAYATG-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YYVPZQADFREIFR-UHFFFAOYSA-N 3,3-difluoropyrrolidine;hydrochloride Chemical compound [Cl-].FC1(F)CC[NH2+]C1 YYVPZQADFREIFR-UHFFFAOYSA-N 0.000 description 1
- ISAZCQOCUOPMNK-UHFFFAOYSA-N 3-[(4-fluorophenoxy)methyl]-5-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]-1,2,4-thiadiazole Chemical compound COC1=CC=CC(CCN2CCN(CC2)C=2SN=C(COC=3C=CC(F)=CC=3)N=2)=C1 ISAZCQOCUOPMNK-UHFFFAOYSA-N 0.000 description 1
- NZNCFXIIEOHIQT-UHFFFAOYSA-N 3-cyclohexyl-5-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]-1,2,4-thiadiazole Chemical compound COC1=CC=CC(CCN2CCN(CC2)C=2SN=C(N=2)C2CCCCC2)=C1 NZNCFXIIEOHIQT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JXCKUPKPRLUIQX-UHFFFAOYSA-N 5-[4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl]-3-(4,4-difluoropiperidin-1-yl)-1,2,4-thiadiazole Chemical compound C1=C(F)C(F)=CC=C1CCN1CCN(C=2SN=C(N=2)N2CCC(F)(F)CC2)CC1 JXCKUPKPRLUIQX-UHFFFAOYSA-N 0.000 description 1
- HILGKYQSOSBIDD-UHFFFAOYSA-N 5-[4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl]-3-(oxan-4-yl)-1,2,4-thiadiazole Chemical compound C1=C(F)C(F)=CC=C1CCN1CCN(C=2SN=C(N=2)C2CCOCC2)CC1 HILGKYQSOSBIDD-UHFFFAOYSA-N 0.000 description 1
- LAIVAIISAXRMAJ-UHFFFAOYSA-N 5-[4-[2-(4-chlorophenyl)ethyl]piperazin-1-yl]-3-(3,3-difluoropyrrolidin-1-yl)-1,2,4-thiadiazole Chemical compound C1C(F)(F)CCN1C1=NSC(N2CCN(CCC=3C=CC(Cl)=CC=3)CC2)=N1 LAIVAIISAXRMAJ-UHFFFAOYSA-N 0.000 description 1
- RZNNFORLSHTQFB-UHFFFAOYSA-N 5-[4-[2-(4-chlorophenyl)ethyl]piperazin-1-yl]-3-(4-fluoropiperidin-1-yl)-1,2,4-thiadiazole Chemical compound C1CC(F)CCN1C1=NSC(N2CCN(CCC=3C=CC(Cl)=CC=3)CC2)=N1 RZNNFORLSHTQFB-UHFFFAOYSA-N 0.000 description 1
- DZUNLEMJMDGDBY-UHFFFAOYSA-N 5-[4-[2-(4-chlorophenyl)ethyl]piperazin-1-yl]-3-[4-(trifluoromethyl)piperidin-1-yl]-1,2,4-thiadiazole Chemical compound C1CC(C(F)(F)F)CCN1C1=NSC(N2CCN(CCC=3C=CC(Cl)=CC=3)CC2)=N1 DZUNLEMJMDGDBY-UHFFFAOYSA-N 0.000 description 1
- GCDRNXNFXVUWAY-UHFFFAOYSA-N 5-[4-[2-(4-chlorophenyl)ethyl]piperazin-1-yl]-3-piperidin-1-yl-1,2,4-thiadiazole Chemical compound C1=CC(Cl)=CC=C1CCN1CCN(C=2SN=C(N=2)N2CCCCC2)CC1 GCDRNXNFXVUWAY-UHFFFAOYSA-N 0.000 description 1
- RLCRLPYZBIUPTQ-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]-3-(oxan-4-yl)-1,2,4-thiadiazole;5-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]-3-(oxan-4-yl)-1,2,4-thiadiazole Chemical compound C1=CC(F)=CC=C1CCN1CCN(C=2SN=C(N=2)C2CCOCC2)CC1.C1=CC(OC)=CC=C1CCN1CCN(C=2SN=C(N=2)C2CCOCC2)CC1 RLCRLPYZBIUPTQ-UHFFFAOYSA-N 0.000 description 1
- AKIIDXSWHDAZEQ-UHFFFAOYSA-N 5-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]-3-(oxan-4-yl)-1,2,4-thiadiazole Chemical compound C1=CC(OC)=CC=C1CCN1CCN(C=2SN=C(N=2)C2CCOCC2)CC1 AKIIDXSWHDAZEQ-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- IFQNLVXMZPIGJC-UHFFFAOYSA-N C(CCC)C1=NSC(=N1)N1CCN(CC1)CCC1=CC(=CC=C1)OC.C1(CC1)C1=NSC(=N1)N1CCN(CC1)CCC1=CC=C(C=C1)OC Chemical compound C(CCC)C1=NSC(=N1)N1CCN(CC1)CCC1=CC(=CC=C1)OC.C1(CC1)C1=NSC(=N1)N1CCN(CC1)CCC1=CC=C(C=C1)OC IFQNLVXMZPIGJC-UHFFFAOYSA-N 0.000 description 1
- XUJXIPIKNKJXDY-UHFFFAOYSA-N C1(CC1)C1=NSC(=N1)N1CCN(CC1)CCC1=CC(=CC=C1)OC.C(CCC)C1=NSC(=N1)N1CCN(CC1)CCC1=CC(=CC=C1)OC Chemical compound C1(CC1)C1=NSC(=N1)N1CCN(CC1)CCC1=CC(=CC=C1)OC.C(CCC)C1=NSC(=N1)N1CCN(CC1)CCC1=CC(=CC=C1)OC XUJXIPIKNKJXDY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004308 Carboxylic Ester Hydrolases Human genes 0.000 description 1
- 108090000863 Carboxylic Ester Hydrolases Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 201000004066 Ganglioglioma Diseases 0.000 description 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000013968 amyotrophic lateral sclerosis-parkinsonism-dementia complex Diseases 0.000 description 1
- 208000014450 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000003092 coiled body Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- PBCFZTOCSCULAL-UHFFFAOYSA-N cyclohexanecarboximidamide Chemical compound NC(=N)C1CCCCC1 PBCFZTOCSCULAL-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 201000005649 gangliocytoma Diseases 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QHCCDDQKNUYGNC-UHFFFAOYSA-N n-ethylbutan-1-amine Chemical compound CCCCNCC QHCCDDQKNUYGNC-UHFFFAOYSA-N 0.000 description 1
- 208000033510 neuroaxonal dystrophy Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000063 preceeding effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177742.1 | 2011-08-17 | ||
| EP11177742 | 2011-08-17 | ||
| PCT/EP2012/066136 WO2013024168A1 (en) | 2011-08-17 | 2012-08-17 | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012296804A1 AU2012296804A1 (en) | 2014-01-30 |
| AU2012296804B2 true AU2012296804B2 (en) | 2017-04-20 |
Family
ID=46826450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012296804A Ceased AU2012296804B2 (en) | 2011-08-17 | 2012-08-17 | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9187440B2 (https=) |
| EP (1) | EP2744798B1 (https=) |
| JP (1) | JP6051218B2 (https=) |
| CN (1) | CN103649062B (https=) |
| AU (1) | AU2012296804B2 (https=) |
| CA (1) | CA2841037C (https=) |
| ES (1) | ES2573299T3 (https=) |
| PL (1) | PL2744798T3 (https=) |
| WO (1) | WO2013024168A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2744798T3 (pl) * | 2011-08-17 | 2016-08-31 | Remynd Nv | Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera |
| WO2015140130A1 (en) * | 2014-03-17 | 2015-09-24 | Remynd Nv | Oxadiazole compounds |
| WO2025104092A1 (en) * | 2023-11-13 | 2025-05-22 | Remynd N.V. | Modulators of septin 6 for use in the prevention and/or treatment of neurodegenerative disorders |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006072436A1 (en) * | 2005-01-07 | 2006-07-13 | F. Hoffmann-La Roche Ag | [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| WO2007090617A2 (en) * | 2006-02-07 | 2007-08-16 | Nv Remynd | Thiadiazole derivatives for the treatment of neuro degenerative diseases |
| WO2008099210A2 (en) * | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| WO2013004642A1 (en) * | 2011-07-01 | 2013-01-10 | Remynd Nv | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004032567A1 (de) | 2004-07-05 | 2006-03-02 | Grünenthal GmbH | Substituierte 1-Propiolyl-piperazine |
| EP1705474B1 (en) | 2005-03-21 | 2010-04-28 | F.Hoffmann-La Roche Ag | Method for determining lipophilicity |
| PE20070099A1 (es) * | 2005-06-30 | 2007-02-06 | Janssen Pharmaceutica Nv | N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso |
| PL2744798T3 (pl) | 2011-08-17 | 2016-08-31 | Remynd Nv | Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera |
-
2012
- 2012-08-17 PL PL12756402T patent/PL2744798T3/pl unknown
- 2012-08-17 ES ES12756402.9T patent/ES2573299T3/es active Active
- 2012-08-17 JP JP2014525462A patent/JP6051218B2/ja not_active Expired - Fee Related
- 2012-08-17 US US14/238,905 patent/US9187440B2/en active Active
- 2012-08-17 CN CN201280034129.3A patent/CN103649062B/zh not_active Expired - Fee Related
- 2012-08-17 EP EP12756402.9A patent/EP2744798B1/en active Active
- 2012-08-17 WO PCT/EP2012/066136 patent/WO2013024168A1/en not_active Ceased
- 2012-08-17 CA CA2841037A patent/CA2841037C/en active Active
- 2012-08-17 AU AU2012296804A patent/AU2012296804B2/en not_active Ceased
-
2015
- 2015-10-15 US US14/884,689 patent/US9808456B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006072436A1 (en) * | 2005-01-07 | 2006-07-13 | F. Hoffmann-La Roche Ag | [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| WO2007090617A2 (en) * | 2006-02-07 | 2007-08-16 | Nv Remynd | Thiadiazole derivatives for the treatment of neuro degenerative diseases |
| WO2008099210A2 (en) * | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| WO2013004642A1 (en) * | 2011-07-01 | 2013-01-10 | Remynd Nv | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1192848A1 (zh) | 2014-09-05 |
| US20140206699A1 (en) | 2014-07-24 |
| ES2573299T3 (es) | 2016-06-07 |
| US9187440B2 (en) | 2015-11-17 |
| CA2841037C (en) | 2020-03-31 |
| US9808456B2 (en) | 2017-11-07 |
| JP6051218B2 (ja) | 2016-12-27 |
| JP2014521737A (ja) | 2014-08-28 |
| AU2012296804A1 (en) | 2014-01-30 |
| US20160101102A1 (en) | 2016-04-14 |
| WO2013024168A1 (en) | 2013-02-21 |
| CA2841037A1 (en) | 2013-02-21 |
| PL2744798T3 (pl) | 2016-08-31 |
| CN103649062B (zh) | 2015-10-07 |
| CN103649062A (zh) | 2014-03-19 |
| EP2744798B1 (en) | 2016-03-30 |
| EP2744798A1 (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012280420B2 (en) | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases | |
| US7541359B2 (en) | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | |
| JP4995076B2 (ja) | Ｇｓｋ−３阻害剤 | |
| US8389743B2 (en) | Histamine-3 receptor antagonists | |
| US20110257171A1 (en) | Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors | |
| US10682358B2 (en) | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | |
| WO2005042525A1 (en) | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | |
| AU2012296804B2 (en) | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease | |
| HK1192848B (en) | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease | |
| CN1898237B (zh) | 嘧啶-4-基-3,4-硫酮化合物及其治疗用途 | |
| HK1192726B (en) | 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | |
| HK1100426B (en) | Thiadiazolidinones as gsk-3 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |